ArticleHepatology communications2026
The incidence, frequency of late liver-related complications, and transplant likelihood in pediatric acute liver failure in Californian children.
Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundEarly studies of pediatric acute liver failure (PALF) estimate that 60%-70% of patients survive with their native liver (SNL), 20%-25% require an emergent liver transplant (LT), and 10%-15% are mortalities. These studies were largely limited to academic centers and focused on short-term outcomes.
methodsHerein, we analyzed California Department of Healthcare Access and Information data, which is demographically representative of the US population. Between June 1990 and December 2018, 2270 children were admitted to California hospitals with PALF.
resultsThe overall incidence of PALF was 16.75 per 100,000 live births, with no evidence of seasonality. LT was performed in 188 (8.3%) patients and 425 (18.7%) patients died. Mortality was associated with contraindications to transplant, such as concomitant hematologic malignancy or cardiac disease. With a median follow-up of 4.5 years, nearly all deaths occurred within 4 months of presentation, with no long-term liver-related comorbidities in patients with SNL. Implementation of pediatric end-stage liver disease/MELD-based organ allocation in 2002 resulted in a more than 2-fold increase in the likelihood of LT in children <10 years (subdistribution hazard ratio: 3.35). Patients receiving care at transplant centers after this change were younger (10 vs. 12 y), more often from urban areas (98.2% vs. 94%), and more likely to receive LT for metabolic, genetic, or "other" causes of PALF (up to subdistribution hazard ratio 6.4 [1.84-22.26], p<0.01). While mortality was higher at transplant centers (26.5% vs. 14.6%), the time to mortality was also increased (31 vs. 7 d), likely reflecting disease complexity requiring management in a specialized children's hospital.
conclusionIn conclusion, this study supports an estimate of incidence and long-term outcomes of PALF across a large population and highlights the role of specialized pediatric transplant centers for the optimized care of PALF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.